Navigation Links
AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force
Date:11/17/2009

NEW HAVEN, Conn., Nov. 17 /PRNewswire/ -- HistoRx today announced that the Company's proprietary AQUA technology, an automated image analysis platform based on tissue-based quantitative immunofluorescence, was noted in a recent National Comprehensive Cancer Network (NCCN) Task Force Report on hormone receptor testing in breast cancer as one of the "... promising new strategies being developed for the measurement of ER and PgR in breast cancer tissue." Experts from the country's leading cancer treatment institutions responded in the report to growing concerns about hormone receptor testing in breast cancer by standard immunohistochemistry (IHC) methodology, particularly a high false-negative rate, and clarified how such testing can be improved. Hormone receptor testing, which includes estrogen receptor (ER) and progesterone receptor (PgR), is a standard part of the diagnostic characterization of an individual's breast cancer and drives treatment decision making.

"The NCCN Task Force Report demonstrates the growing confidence within oncology circles that AQUA analysis provides a new and promising approach to hormone receptor testing," said Rana K. Gupta, CEO of HistoRx. "We believe the upcoming ASCO-CAP guidelines will reinforce the Task Force's assessment that current methods of ER testing are flawed and will further underscore the need for a better solution. AQUA technology's sensitivity, reproducibility and quantification improve upon standard immunohistochemistry testing and can play an important role in improving the overall accuracy of hormone receptor testing."

An early example of personalized medicine, ER testing and PgR testing are typically performed by standard IHC. AQUA® technology brings standardization and reproducibility to IHC analysis and is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections. This advance enables fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. AQUA's proprietary software uses automated fluorescent image acquisition and data analysis to provide precise quantification of protein biomarkers of interest, including hormone receptors. HistoRx has developed ER and PgR tests based on AQUA® technology. Both of these assays have been used to analyze the TEAM trial, a randomized, international study of more than 9,000 postmenopausal women with hormone sensitive early breast cancer. Results from this analysis will be discussed at the San Antonio Breast Cancer Symposium in December 2009.

[About HistoRx] HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis. AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.

SOURCE HistoRx, Inc.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
(Date:4/27/2016)... , April 27, 2016 ... of the  "Global Anesthesia Disposables Market 2016-2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ,The global anesthesia disposables ... CAGR of 4.03% during the period 2016-2020.  ... major threat to patients, safety. Organizations like ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Powerful tools of hypnosis, ... O'Maley. What is hypnosis and hypnotherapy and why after centuries, it is ... relief (chronic and acute), birthing processes and medical procedures, depression, anxiety, fear reactions, ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor ... of EMED, today signed a multifaceted agreement which will allow for the research ... University Department of Natural and Applied Sciences, Allied Health and Nursing will work ...
(Date:4/30/2016)... , ... April 30, 2016 , ... Orlando-based Maximized Living ... they go for gold in Rio. Under the care of Maximized Living doctors ... , In an unprecedented showing, Maximized Living is sending the largest contingent of elite ...
(Date:4/29/2016)... Los Angeles, CA (PRWEB) , ... April 29, 2016 , ... ... Sarah Mirmelli, a mother and divorcee, shares her enthusiasm for Botox and lip injections, ... of the world famous youth oriented Coachella Valley Music and Arts Festival. The article ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... and Spiritual Awakening , announces the addition Onnit brand Alpha BRAIN and New ... addition of Onnit brain and mood optimization products to the store is just ...
Breaking Medicine News(10 mins):